Two independent studies in 2017 proposed that targeting PARP-mediated DNA repair could be a promising strategy for IDH-mutant gliomas, even if each claimed a different molecular mechanism responsible for this finding [104]. This evidence concerns the gene IDH1 and central nervous system cancer.